Risk factors and effective management of preeclampsia
Open Access
- 1 March 2015
- journal article
- review article
- Published by Taylor & Francis in Integrated Blood Pressure Control
- Vol. 8, 7-12
Abstract
Preeclampsia, a hypertensive disorder of pregnancy is estimated to complicate 2%–8% of pregnancies and remains a principal cause of maternal and fetal morbidity and mortality. Preeclampsia may present at any gestation but is more commonly encountered in the third trimester. Multiple risk factors have been documented, including: family history, nulliparity, egg donation, diabetes, and obesity. Significant progress has been made in developing tests to predict risk of preeclampsia in pregnancy, but these remain confined to clinical trial settings and center around measuring angiogenic profiles, including placental growth factor or newer tests involving metabolomics. Less progress has been made in developing new treatments and therapeutic targets, and aspirin remains one of the few agents shown to consistently reduce the risk of developing preeclampsia. This review serves to discuss recent advances in risk factor identification, prediction techniques, and management of preeclampsia in antenatal, intrapartum, and postnatal patients.Keywords
This publication has 40 references indexed in Scilit:
- IFPA Senior Award Lecture: Making sense of pre-eclampsia – Two placental causes of preeclampsia?Placenta, 2014
- The vascular endothelial growth factor family in adverse pregnancy outcomesHuman Reproduction Update, 2012
- Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms‐like tyrosine kinase 1 and soluble endoglin in the prediction of pre‐eclampsia: a systematic review and meta‐analysisBJOG: An International Journal of Obstetrics & Gynaecology, 2012
- Maternal Preeclampsia and Neonatal OutcomesJournal of Pregnancy, 2011
- How useful is uterine artery Doppler ultrasonography in predicting pre-eclampsia and intrauterine growth restriction?Canadian Medical Association Journal, 2008
- Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysisBMJ, 2007
- Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trialThe Lancet, 2002
- Vascular Endothelial Growth Factor Ligands and Receptors That Regulate Human Cytotrophoblast Survival Are Dysregulated in Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Low Platelets SyndromeThe American Journal of Pathology, 2002
- Neonatal outcome after preterm delivery for preeclampsiaAmerican Journal of Obstetrics and Gynecology, 1995
- PREGNANCY OUTCOME IN 303 CASES WITH SEVERE PREECLAMPSIA1984